NewAmsterdam Pharma (NAMS) Non-Current Assets (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Non-Current Assets of $74.6 million for Q1 2026, down 20.29% sequentially from $93.6 million in Q4 2025, and up 6626.69% YoY from $1.1 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Non-Current Assets (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Non-Current Assets for 6 years, with the latest figure at $74.6 million in Q1 2026.
- Quarterly Non-Current Assets rose 6626.69% year-over-year to $74.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $267.5 million (up 5282.1% YoY) and the FY2025 annual result came in at $93.6 million, up 7653.44% from the prior year.
- Non-Current Assets slipped to $74.6 million in Q1 2026 per NAMS's latest filing, from $93.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $93.6 million in Q4 2025 and troughed at $306000.0 in Q4 2023.
- A 5-year average of $37.3 million and a median of $23.3 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 8196447.84% in 2022, then tumbled 99.64% in 2023.
- Over 5 years, Non-Current Assets stood at $85.1 million in 2022, then sank by 99.64% to $306000.0 in 2023, then jumped by 294.44% to $1.2 million in 2024, then jumped by 7653.44% to $93.6 million in 2025, then slipped by 20.29% to $74.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $74.6 million, $93.6 million, and $54.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 45.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.25 Mn |
| Mar 31, 2026 | 74.60 Mn |
| Dec 31, 2025 | 93.58 Mn |
| Sep 30, 2025 | 54.10 Mn |
| Jun 30, 2025 | 45.26 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 641,000.00 |
| Dec 31, 2023 | 306,000.00 |
| Jun 30, 2023 | 89.11 Mn |
| Dec 31, 2022 | 85.14 Mn |
| Dec 31, 2021 | 1,038.73 |